Propofol induces apoptosis and increases gemcitabine sensitivity in pancreatic cancer cells in vitro by inhibition of nuclear factor-κB activity

World Journal of Gastroenterology

Volumn 19, Issue 33, 2013, Pages 5485-5492

  Du, Qi Hang ^a   Xu, Yan Bing ^a   Zhang, Meng Yuan ^a   Yun, Peng ^a   He, Chang Yao ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Apoptosis; Gemcitabine; Nuclear factor B; Pancreatic cancer; Propofol

Indexed keywords

GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROPOFOL;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; DNA BINDING; DNA FRAGMENTATION; DOWN REGULATION; DRUG SENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; NICK END LABELING; PANCREAS CANCER; SINGLE DRUG DOSE; UPREGULATION;

APOPTOSIS; GEMCITABINE; NUCLEAR FACTOR-ΚB; PANCREATIC CANCER; PROPOFOL;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; HUMANS; HYPNOTICS AND SEDATIVES; NF-KAPPA B; PANCREATIC NEOPLASMS; PROPOFOL;

EID: 84883529354     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i33.5485     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-130 [PMID: 16514137 DOI: 10.3322/canjclin.56.2.106]
2. O'Reilly EM, Abou-Alfa GK. Cytotoxic therapy for advanced pancreatic adenocarcinoma. Semin Oncol 2007; 34: 347-353 [PMID: 17674963 DOI: 10.1053/j.seminoncol.2007.05.009]
3. Long J, Zhang Y, Yu X, Yang J, LeBrun DG, Chen C, Yao Q, Li M. Overcoming drug resistance in pancreatic cancer. Expert Opin Ther Targets 2011; 15: 817-828 [PMID: 21391891 DOI: 10.1517/14728222.2011.566216]
4. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966 [PMID: 17452677 DOI: 10.1200/JCO.2006.07.9525]
5. Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005; 5: 297-309 [PMID: 15803156 DOI: 10.1038/nrc1588]
6. Pan X, Arumugam T, Yamamoto T, Levin PA, Ramachandran V, Ji B, Lopez-Berestein G, Vivas-Mejia PE, Sood AK, McConkey DJ, Logsdon CD. Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells. Clin Cancer Res 2008; 14: 8143-8151 [PMID: 19088029 DOI: 10.1158/1078-0432.CCR-08-1539]
7. Kong R, Sun B, Jiang H, Pan S, Chen H, Wang S, Krissansen GW, Sun X. Downregulation of nuclear factor-kappaB p65 subunit by small interfering RNA synergizes with gemcitabine to inhibit the growth of pancreatic cancer. Cancer Lett 2010; 291: 90-98 [PMID: 19880242 DOI: 10.1016/j.canlet.2009.10.001]
8. Ahn DW, Seo JK, Lee SH, Hwang JH, Lee JK, Ryu JK, Kim YT, Yoon YB. Enhanced antitumor effect of combination therapy with gemcitabine and guggulsterone in pancreatic cancer. Pancreas 2012; 41: 1048-1057 [PMID: 22513291 DOI: 10.1097/MPA.0b013e318249d62e]
9. Guo HC, Bu HQ, Luo J, Wei WT, Liu DL, Chen H, Tong HF, Wang ZH, Wu HY, Li HH, Zuo MM, Li W, Lin SZ. Emodin potentiates the antitumor effects of gemcitabine in PANC-1 pancreatic cancer xenograft model in vivo via inhibition of inhibitors of apoptosis. Int J Oncol 2012; 40: 1849-1857 [PMID: 22378302]
10. Wang YW, Wang SJ, Zhou YN, Pan SH, Sun B. Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in pancreatic cancer both in vitro and in vivo. J Cancer Res Clin Oncol 2012; 138: 785-797 [PMID: 22270965 DOI: 10.1007/s00432-012-1152-z]
11. Velly LJ, Guillet BA, Masmejean FM, Nieoullon AL, Bruder NJ, Gouin FM, Pisano PM. Neuroprotective effects of propofol in a model of ischemic cortical cell cultures: role of glutamate and its transporters. Anesthesiology 2003; 99: 368-375 [PMID: 12883409 DOI: 10.1097/00000542-200308000-00018]
12. Zheng YY, Lan YP, Tang HF, Zhu SM. Propofol pretreatment attenuates aquaporin-4 over-expression and alleviates cerebral edema after transient focal brain ischemia reperfusion in rats. Anesth Analg 2008; 107: 2009-2016 [PMID: 19020152 DOI: 10.1213/ane.0b013e318187c313]
13. Cui D, Wang L, Qi A, Zhou Q, Zhang X, Jiang W. Propofol prevents autophagic cell death following oxygen and glucose deprivation in PC12 cells and cerebral ischemiareperfusion injury in rats. PLoS One 2012; 7: e35324 [PMID: 22509406 DOI: 10.1371/journal.pone.0035324]
14. Xi HJ, Zhang TH, Tao T, Song CY, Lu SJ, Cui XG, Yue ZY. Propofol improved neurobehavioral outcome of cerebral ischemia-reperfusion rats by regulating Bcl-2 and Bax expression. Brain Res 2011; 1410: 24-32 [PMID: 21783180 DOI: 10.1016/j.brainres.2011.06.060]
15. Li J, Han B, Ma X, Qi S. The effects of propofol on hippocampal caspase-3 and Bcl-2 expression following forebrain ischemia-reperfusion in rats. Brain Res 2010; 1356: 11-23 [PMID: 20707988 DOI: 10.1016/j.brainres.2010.08.012]
16. Ye HH, Wu KJ, Fei SJ, Zhang XW, Liu HX, Zhang JL, Zhang YM. Propofol participates in gastric mucosal protection through inhibiting the toll-like receptor-4/nuclear factor kappa-B signaling pathway. Clin Res Hepatol Gastroenterol 2013; 37: e3-15 [PMID: 22516481 DOI: 10.1016/j.clinre.2012.03.004]
17. Siddiqui RA, Zerouga M, Wu M, Castillo A, Harvey K, Zaloga GP, Stillwell W. Anticancer properties of propofol-docosahexaenoate and propofol-eicosapentaenoate on breast cancer cells. Breast Cancer Res 2005; 7: R645-R654 [PMID: 16168109 DOI: 10.1186/bcr1036]
18. Wu KC, Yang ST, Hsia TC, Yang JS, Chiou SM, Lu CC, Wu RS, Chung JG. Suppression of cell invasion and migration by propofol are involved in down-regulating matrix metalloproteinase-2 and p38 MAPK signaling in A549 human lung adenocarcinoma epithelial cells. Anticancer Res 2012; 32: 4833-4842 [PMID: 23155249]
19. Zhang L, Wang N, Zhou S, Ye W, Jing G, Zhang M. Propofol induces proliferation and invasion of gallbladder cancer cells through activation of Nrf2. J Exp Clin Cancer Res 2012; 31: 66 [PMID: 22901367 DOI: 10.1186/1756-9966-31-66]
20. Li Q, Zhang L, Han Y, Jiang Z, Wang Q. Propofol reduces MMPs expression by inhibiting NF-κB activity in human MDA-MB-231 cells. Biomed Pharmacother 2012; 66: 52-56 [PMID: 22264881 DOI: 10.1016/j.biopha.2011.10.006]
21. Lai HC, Yeh YC, Wang LC, Ting CT, Lee WL, Lee HW, Wang KY, Wu A, Su CS, Liu TJ. Propofol ameliorates doxorubicin-induced oxidative stress and cellular apoptosis in rat cardiomyocytes. Toxicol Appl Pharmacol 2011; 257: 437-448 [PMID: 22015447 DOI: 10.1016/j.taap.2011.10.001]
22. Arlt A, Gehrz A, Müerköster S, Vorndamm J, Kruse ML, Fölsch UR, Schäfer H. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 2003; 22: 3243-3251 [PMID: 12761494 DOI: 10.1038/sj.onc.1206390]
23. Brasil LJ, San-Miguel B, Kretzmann NA, Amaral JL, Zettler CG, Marroni N, González-Gallego J, Tuñón MJ. Halothane induces oxidative stress and NF-kappaB activation in rat liver: protective effect of propofol. Toxicology 2006; 227: 53-61 [PMID: 16965849 DOI: 10.1016/j.tox.2006.07.013]
24. Berlin JD, Rothenberg ML. Chemotherapeutic advances in pancreatic cancer. Curr Oncol Rep 2003; 5: 219-226 [PMID: 12667419 DOI: 10.1007/s11912-003-0113-8]
25. Diaz-Rubio E. New chemotherapeutic advances in pancreatic, colorectal, and gastric cancers. Oncologist 2004; 9: 282-294 [PMID: 15169983 DOI: 10.1634/theoncologist.9-3-282]
26. Arends JJ, Sleeboom HP, Leys MB, Ten Bokkel Huinink D, de Jong RS, Smit JM, Nortier JW, Tesselaar ME. A phase II study of raltitrexed and gemcitabine in patients with advanced pancreatic carcinoma. Br J Cancer 2005; 92: 445-448 [PMID: 15668704]
27. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825 [PMID: 21561347 DOI: 10.1056/NEJMoa1011923.]
28. Ergün R, Akdemir G, Sen S, Taşçi A, Ergüngör F. Neuroprotective effects of propofol following global cerebral ischemia in rats. Neurosurg Rev 2002; 25: 95-98 [PMID: 11954772 DOI: 10.1007/s101430100171]
29. Fu L, Tang R, Bao N, Wang J, Ma H. Ketamine and propofol in combination induce neuroapoptosis and down-regulate the expression of N-methyl-D-aspartate glutamate receptor NR2B subunit in rat forebrain culture. Pharmazie 2011; 66: 771-776 [PMID: 22026159]
30. Huang Y, Zitta K, Bein B, Scholz J, Steinfath M, Albrecht M. Effect of propofol on hypoxia re-oxygenation induced neuronal cell damage in vitro*. Anaesthesia 2013; 68: 31-39 [PMID: 23088185 DOI: 10.1111/j.1365-2044.2012.07336.x]